NIS on the Benefits of TIPS in Patients With HCC Receiving Atezo+Bev in 1st-Line Therapy
Recruiting now
Conditions studied: Hepatocellular Carcinoma (HCC)
In brief
The NISTIPS TRITICC-4 study is a prospective, multicentre, non-interventional cohort study to analyze the effectiveness of transjugular intrahepatic portosystemic shunting (TIPS) in patients with Hepatocellular carcinoma (HCC) receiving atezolizumab plus bevacizumab as first-line treatment. It will further characterize the effectiveness of atezolizumab and bevacizumab therapy, investigate post-market safety and evaluate health-related quality in HCC patient cohorts with or without TIPS in a real-world setting.
Key facts
- Study ID
- NCT07365930
- Run by
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
- People needed
- 350
- Starts
- 2025-12-17
- Expected to finish
- 2031-12-17
- Last updated by the study team
- 2026-02-05
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- The patient has a histologically confirmed, locally advanced or metastatic and/or unresectable HCC with:
- the presence of liver cirrhosis (cirrhosis confirmed by histology or liver stiffness or with unequivocal signs in ultrasound, endoscopy, and/or blood tests),
- a disease that is not amenable to curative surgical and/or locoregional therapies, or a progressive disease after surgical and /or locoregional therapies,
- A decision for treatment with atezolizumab + bevacizumab according to the market authorization with or without TIPS has been made before enrolling into the study by the treating physician.
- NOTE: Patients who have already received 1-2 cycles of atezo+bev therapy are eligible for enrollment into the NISTIPS TRITICC-4 study, when the prescription of the medicine or other therapeutic strategies are clearly separated from the decision to include the patient in the study.
You may not qualify if…
- The patient has not provided signed informed consent.
- The patient is under 18 years of age at the time of giving signed informed consent.
- The patient is unable to understand all implications of study participation.
Where it is running
- University Hospital of Düsseldorf — Düsseldorf, North Rhine-Westphalia, Germany (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.